AR125919A2 - SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS - Google Patents
SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMSInfo
- Publication number
- AR125919A2 AR125919A2 ARP220101336A ARP220101336A AR125919A2 AR 125919 A2 AR125919 A2 AR 125919A2 AR P220101336 A ARP220101336 A AR P220101336A AR P220101336 A ARP220101336 A AR P220101336A AR 125919 A2 AR125919 A2 AR 125919A2
- Authority
- AR
- Argentina
- Prior art keywords
- ruxolitinib
- dosage forms
- sustained
- release
- useful
- Prior art date
Links
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a formulaciones de liberación sostenida y formas de dosificación de ruxolitinib o su sal farmacéuticamente aceptable, que son útiles en el tratamiento de enfermedades relacionadas con las quinasa Janus como trastornos mieloproliferativos.The present invention relates to sustained release formulations and dosage forms of ruxolitinib or its pharmaceutically acceptable salt, which are useful in the treatment of Janus kinase-related diseases such as myeloproliferative disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726893P | 2012-11-15 | 2012-11-15 | |
| US202061769408P | 2020-02-26 | 2020-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125919A2 true AR125919A2 (en) | 2023-08-23 |
Family
ID=87886787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101336A AR125919A2 (en) | 2012-11-15 | 2022-05-19 | SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR125919A2 (en) |
-
2022
- 2022-05-19 AR ARP220101336A patent/AR125919A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150265A (en) | DOSAGE FORMS OF SUSTAINED RUXOLITINIB LIBERATION | |
| CY1124311T1 (en) | DNA-PK INHIBITORS | |
| CY1125436T1 (en) | DNA-PK INHIBITORS | |
| UY33616A (en) | COMPOUNDS WITH IMIDAZOTRIAZINONA STRUCTURE | |
| UY33863A (en) | METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX386935B (en) | PRODRUGS OF FUMARATES AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES. | |
| CL2014001752A1 (en) | Substituted bicyclic compounds; pharmaceutical composition that includes them; and use in the treatment of diseases such as cancer, Alzheimer's, AIDS, among others. | |
| PE20151788A1 (en) | TETRACYCLIC BROMODOMINES INHIBITORS | |
| DOP2014000115A (en) | USE OF SUBSTITUTED 4-PHENYL-PYRIDINS FOR THE MANUFACTURE OF USEFUL MEDICINES IN THE TREATMENT OF DISEASES RELATED TO THE NK1 RECEIVER | |
| EA201591616A1 (en) | TRIFTTOROMETHYL-SUBSTITUTED ANNELATED PYRIMIDINES AND THEIR APPLICATION | |
| CU20160151A7 (en) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHYDROPIRANE [3,4-d] [1,3] TIAZIN-8a (8H) -IL-1,3-TIAZOL-4-ILAMIDAS | |
| ECSP13012824A (en) | DERIVATIVES OF (1,2,4) TRIAZOLO [4,3-A) QUINOXALINE AS PHOSPHODESTERASE INHIBITORS | |
| MX389847B (en) | COMPOSITIONS OF CANNABIDIOLIC ACID ESTERS AND THEIR USES. | |
| MX2015007774A (en) | THERAPEUTICALLY ACTIVE PIRAZOLO-PYRIMIDINE DERIVATIVES. | |
| EA201291211A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE | |
| NI201600070A (en) | AUTOTAXIN TETRAYCLIC INHIBITORS | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX2015009277A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
| TR201908151T4 (en) | Isoindoline derivatives. | |
| MX2016000037A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| MX2017005163A (en) | Onapristone extended-release compositions and methods. | |
| UA112488C2 (en) | THREE (HETERO) ARILPYRAZOLES AND THEIR APPLICATIONS | |
| AR125919A2 (en) | SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS | |
| ECSP15025357A (en) | SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS | |
| PH12019501070A1 (en) | Sustained-release dosage forms of ruxolitinib |